$CRVO News

CervoMed Reports First Quarter 2026 Financial Results and Provides Corporate Updates

CervoMed Q1 EPS $(0.86) Misses $(0.78) Estimate

Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Misses Revenue Estimates

IDEAYA Biosciences, Inc. (IDYA) Reports Q1 Loss, Misses Revenue Estimates

HC Wainwright & Co. Reiterates Buy on CervoMed, Maintains $25 Price Target

CervoMed Announces New Data at the 2026 AAN Annual Meeting that Demonstrated Neflamapimod Increased Basal Forebrain Volume and Functional Connectivity in Dementia with Lewy Bodies

CervoMed Presents Data On Neflamapimod That May Increase Size, Enhance Function Of Basal Forebrain In Participants With Dementia With Lewy Bodies

CervoMed to Provide Neflamapimod Clinical Program Update and Participate in a Panel on Biomarkers at 2026 Lewy Body Dementia Association Annual Meeting

CervoMed To Present Key Aspects Of Neflamapimod Clinical Program At 2026 Lewy Body Dementia Association Annual Meeting, Including Updates On Clinical Findings, Global Regulatory Alignment, And Finalized Phase 3 Trial Design In DLB

CervoMed (CRVO)’s Q4 Results Feature Advancements in Its Neflamapimod Program for Dementia Lewy Bodies (DLB)

CervoMed Announces New Data at the AD/PD™ 2026 Scientific Conference that Reinforce Neflamapimod’s Positive Effects in Dementia with Lewy Bodies (DLB) in Patients without Alzheimer’s Disease Co-Pathology

Investigators To Present New Analyses From Phase 2b RewinD-LB Clinical Study Of Neflamapimod Being Developed By Cervomed

Roth Capital Maintains Buy on CervoMed, Lowers Price Target to $11

Chardan Capital Maintains Buy on CervoMed, Raises Price Target to $21

CervoMed Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates

CervoMed Q4 EPS $(0.88) Misses $(0.63) Estimate, Sales $8.726M Beat $966.667K Estimate

CervoMed Inc. (CRVO) Reports Q4 Loss, Lags Revenue Estimates

CervoMed Announces Presentations at Upcoming AD/PD™ 2026 Scientific Conference

CervoMed to Participate in Upcoming Investor Conferences

CervoMed Announces Selection of Formulation and Dosing Regimen for Planned Phase 3 Trial in Patients with Dementia with Lewy Bodies